![]() |
市場調查報告書
商品編碼
1346714
苯丙胺酸市場:現況分析與預測(2022-2030)Phenylalanine Market: Current Analysis and Forecast (2022-2030) |
由於大豆和豌豆等許多植物蛋白來源中苯丙胺酸含量較高,苯丙胺酸市場在預測期內(2023-2030年)複合年增長率為3.8%,預計增長強勁。 此外,隨著精神疾病盛行率的上升,對含有苯丙胺酸或其衍生物的補充劑的需求增加,預計該市場在未來幾年將擴大。 根據美國國家慢性病預防與健康促進中心的數據,到 2023 年,美國將有超過五分之一的成年人患有精神疾病。 現在或一生中的某個階段,超過五分之一的年輕人(13 至 18 歲)都受到嚴重且令人衰弱的精神疾病的影響。
市場依類型分為 L-苯丙胺酸、D-苯丙胺酸和 DL-苯丙胺酸。 其中,醫藥和食品業對L-苯丙胺酸的需求不斷增加,並在2022年佔據市場主導地位。 此外,人們對 L-苯丙胺酸益處的認識不斷提高也促進了市場的成長。
根據應用,市場分為憂鬱症、注意力不足過動症、巴金森氏症、慢性疼痛、白斑症等。 其中,憂鬱症預計在預測期(2023-2030年)將以較大的複合年增長率成長。 雖然苯丙胺酸在多巴胺的產生中發揮重要作用,有助於緩解憂鬱症,但它也與越來越多的憂鬱症和精神疾病有關。 根據人口健康部門的數據,到 2023 年 4 月,美國大約每 25 名成年人中就有 1 人患有嚴重精神疾病,如精神分裂症、躁鬱症或重度憂鬱症。
依最終用戶劃分,市場分為食品和飲料、營養補充品、藥品等。 預計食品和飲料類別在預測期內(2023-2030 年)將以顯著的複合年增長率成長。 這是因為它廣泛用於生產各種食品和飲料產品。 常用作增味劑、營養源及防腐劑。 它廣泛用於食品工業製造阿斯巴甜和三氯蔗糖等人工甜味劑。
為了更了解苯丙胺類產業的市場介紹,將市場分為北美(美國、加拿大、北美其他地區)、歐洲(德國、英國、法國、義大利、西班牙、歐洲其他地區)、亞太地區(中國、日本、印度、韓國等亞太地區國家)及全球其他國家。 由於對富含蛋白質的食品的需求不斷增加以及糖尿病、心臟病和癌症等慢性疾病的患病率不斷增加,2022年的苯丙氨酸市場由北美主導,這往往與不健康的飲食習慣和缺乏運動有關。 根據 2021 年 IDF 糖尿病圖譜,20 歲至 79 歲之間的成年人中有 10.5% 患有糖尿病,其中近一半人不知道自己患有糖尿病。 根據 IDF 預測,到 2045 年,約有 7.83 億人(即八分之一的人)患有糖尿病,增幅為 46%。 需要苯丙胺酸來製造治療這些疾病的藥物,隨著患有慢性病的人數持續成長,苯丙胺酸的市場也將持續成長。
The body uses phenylalanine which is an essential amino acid, to make proteins and other compounds. It is also a precursor to the neurotransmitters dopamine, norepinephrine, and serotonin involved in regulating mood, motivation, and other aspects of mental health. The surge in demand for phenylalanine and its subordinates is driven by various elements, including the development of the food and drink industry, the rising prominence of plant-based diets with fewer calories, and the rising predominance of emotional well-being problems such as anxiety and depression.
The Phenylalanine Market is expected to grow at a strong CAGR of 3.8% during the forecast period (2023-2030) owing to the rising demand for phenylalanine, as many plant-based protein sources such as soybeans and peas contain high levels of phenylalanine. Adding to this, the market is anticipated to expand in the forecast years due to the rising prevalence of mental health disorders has led to a growing demand for supplements that contain phenylalanine or its derivatives. As per the National Center for Chronic Disease Prevention and Health Promotion, in 2023, over 1 in 5 adults in the United States suffer from mental illness. A seriously debilitating mental illness has affected more than one in five young people (ages 13 to 18) either now or at some point in their lives.
Based on the type, the market is segmented into L-phenylalanine, D-phenylalanine, and DL-phenylalanine. Amongst these, the L-phenylalanine segment dominated the market in 2022 due to the expanding requirement for L-phenylalanine in the pharmaceutical and food industries. Also, the rising awareness of the advantages of L-phenylalanine is also contributing to the growth of the market.
By application, the market is segmented into depression, attention deficit disorder, Parkinson's disease, chronic pain, vitiligo, and others. Among these, depression is expected to grow with a significant CAGR during the forecast period (2023-2030). The rising number of depression and mental health disorders while phenylalanine supports depression relief because it plays a crucial role in the production of dopamine. According to the Division of Population Health, in April 2023, approximately one in every 25 adults in the United States, adults lives with a serious mental illness, such as schizophrenia, bipolar disorder, or major depression.
On the basis of end-users, the market is segmented into food and beverage, dietary supplements, pharmaceuticals, and others. The food and beverage category is expected to grow at a substantial CAGR during the forecasted period (2023-2030). This is because of widely used in the production of a wide range of food and beverage products. It is commonly used as a flavor enhancer, a source of nutrition, and a preservative. In the food industry, this is extensively used in the production of artificial sweeteners, such as aspartame and sucralose
For a better understanding of the market adoption of the phenylalanine industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. North America dominated the phenylalanine market in 2022 due to the increasing demand for protein-rich foods, and the increasing prevalence of chronic diseases such as diabetes, heart disease, and cancer that are becoming more prevalent and are frequently linked to unhealthy eating habits and inactivity. According to the IDF Diabetes Atlas in 2021, 10.5% of adults aged 20 to 79 have diabetes, and nearly half of them are unaware that they have the condition. According to IDF projections, approximately 783 million adults-or 1 in 8-will have diabetes by 2045, an increase of 46%. The production of medicines to treat these conditions necessitates phenylalanine, and as the number of people living with chronic conditions continues to rise the market for phenylalanine.
Some of the major players operating in the market include: Ajinomoto Co., Inc.; DAESANG; Livzon; KYOWA HAKKO BIO CO., LTD.; Amazing Nutrition; AMINO GmbH; Wuxi Jinghai Amino Acid Co., Ltd.; Shijiazhuang Jirong Pharmaceutical Co., Ltd.; Shijiazhuang Haitian Amino Acid Co., Ltd.; NOW Foods.